Total Payments
$186,032
2024 Payments
$4,760
Companies
11
Transactions
151
Medicare Patients
326
Medicare Billing
$44,066
Payment Breakdown by Category
Consulting$104,870 (56.4%)
Other$35,896 (19.3%)
Research$23,665 (12.7%)
Travel$18,808 (10.1%)
Food & Beverage$2,794 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $104,870 | 30 | 56.4% |
| Unspecified | $23,665 | 21 | 12.7% |
| Honoraria | $21,400 | 3 | 11.5% |
| Travel and Lodging | $18,808 | 39 | 10.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,496 | 12 | 7.8% |
| Food and Beverage | $2,794 | 46 | 1.5% |
Payments by Type
General
$162,367
130 transactions
Research
$23,665
21 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $56,673 | 26 | $0 (2024) |
| Gilead Sciences, Inc. | $35,256 | 32 | $0 (2021) |
| GENZYME CORPORATION | $32,142 | 16 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $15,243 | 23 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $12,010 | 16 | $0 (2020) |
| Regeneron Pharmaceuticals, Inc. | $11,309 | 13 | $0 (2019) |
| ABBVIE INC. | $9,905 | 14 | $0 (2022) |
| Genentech, Inc. | $6,753 | 6 | $0 (2018) |
| Janssen Scientific Affairs, LLC | $6,360 | 3 | $0 (2019) |
| Eli Lilly and Company | $350.00 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,760 | 3 | PFIZER INC. ($4,760) |
| 2023 | $7,644 | 4 | PFIZER INC. ($6,700) |
| 2022 | $25,631 | 16 | PFIZER INC. ($17,870) |
| 2021 | $20,000 | 4 | PFIZER INC. ($11,200) |
| 2020 | $20,635 | 12 | GENZYME CORPORATION ($8,131) |
| 2019 | $47,737 | 68 | Gilead Sciences, Inc. ($15,451) |
| 2018 | $47,319 | 37 | GENZYME CORPORATION ($22,590) |
| 2017 | $12,305 | 7 | PFIZER INC. ($5,529) |
All Payment Transactions
151 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/25/2024 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $780.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 03/12/2024 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $780.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 01/23/2024 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/04/2023 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/02/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 05/22/2023 | PFIZER INC. | XELJANZ (Drug) | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 01/31/2023 | GENZYME CORPORATION | KEVZARA (Biological) | Consulting Fee | Cash or cash equivalent | $594.00 | General |
| Category: Rheumatology | ||||||
| 11/17/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,950.00 | General |
| 11/03/2022 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $162.63 | General |
| 11/01/2022 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $449.57 | General |
| 11/01/2022 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $297.00 | General |
| 11/01/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $120.09 | General |
| 11/01/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $59.06 | General |
| 11/01/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $42.95 | General |
| 11/01/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $29.53 | General |
| 11/01/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $24.16 | General |
| 07/07/2022 | PFIZER INC. | XELJANZ (Drug) | Honoraria | Cash or cash equivalent | $11,800.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/19/2022 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/03/2022 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/21/2022 | PFIZER INC. | XELJANZ (Drug) | Honoraria | Cash or cash equivalent | $1,600.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 02/14/2022 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $826.50 | General |
| 01/24/2022 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TOFACITINIB SPA CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 01/20/2022 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/23/2021 | AbbVie Inc. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: IMMUNOLOGY | ||||||
| 05/28/2021 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $19,040 | 10 |
| A randomized, double-blind, placebo-controlled, multicenter, two-part, dose ranging and confirmatory study with an operationally seamless design, evaluating efficacy and safety of SAR153191 on top of methotrexate in patients with active rheumatoid arthrit | GENZYME CORPORATION | $1,603 | 2 |
| Data-driven patient clustering and differential clinical outcomes in the BRASS rheumatoid arthritis registry | SANOFI-AVENTIS U.S. LLC | $959.04 | 2 |
| Exploring Heterogeneity in Rheumatoid Arthritis: Outcomes up to 4 Years of Follow-Up in Patient Clusters Identified by Data-driven Analysis of The BRASS Registry | SANOFI-AVENTIS U.S. LLC | $748.00 | 2 |
| Exploring Heterogeneity in Rheumatoid Arthritis: Patient Profiling through Principal Component and Cluster Analysis of The Brass Registry | SANOFI-AVENTIS U.S. LLC | $612.00 | 2 |
| TOFACITINIB SPA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women?s Rheumatoid Arthritis Sequential Study (BRASS) Registry | SANOFI-AVENTIS U.S. LLC | $226.44 | 1 |
| Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Womens Rheumatoid Arthritis Sequential Study (BRASS) Registry | SANOFI-AVENTIS U.S. LLC | $146.52 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 123 | 136 | $34,436 | $11,335 |
| 2022 | 1 | 76 | 143 | $41,327 | $13,402 |
| 2021 | 1 | 77 | 129 | $37,281 | $12,900 |
| 2020 | 1 | 50 | 84 | $24,276 | $6,430 |
Total Patients
326
Total Services
492
Medicare Billing
$44,066
Procedure Codes
5
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 69 | 77 | $17,017 | $6,037 | 35.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 54 | 59 | $17,419 | $5,298 | 30.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 76 | 143 | $41,327 | $13,402 | 32.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 77 | 129 | $37,281 | $12,900 | 34.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 50 | 84 | $24,276 | $6,430 | 26.5% |
About Clifton Bingham
Clifton Bingham is a Rheumatology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1972569655.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Clifton Bingham has received a total of $186,032 in payments from pharmaceutical and medical device companies, with $4,760 received in 2024. These payments were reported across 151 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($104,870).
As a Medicare-enrolled provider, Bingham has provided services to 326 Medicare beneficiaries, totaling 492 services with total Medicare billing of $44,066. Data is available for 4 years (2020–2023), covering 5 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Baltimore, MD
- Active Since 04/22/2006
- Last Updated 06/07/2013
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1972569655
Products in Payments
- XELJANZ (Drug) $56,673
- KEVZARA (Drug) $32,821
- KEVZARA (Biological) $17,145
- ORENCIA (Biological) $10,108
- Actemra (Biological) $6,753
- SIMPONI ARIA (Biological) $6,360
- RINVOQ (Biological) $3,600
- KEVZARA SARILUMAB INJECTION (Biological) $3,036
- DUPIXENT (Biological) $1,632
- Humira (Biological) $541.88
- RINVOQ (Drug) $500.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Baltimore
Michelle Petri, M.d, M.D
Rheumatology — Payments: $402,963
Rheumatology $402,963
Dr. Marc Hochberg, M.d, M.D
Rheumatology — Payments: $193,354
Rheumatology $193,354
Dr. Philip Seo, Md, Mhs, MD, MHS
Rheumatology — Payments: $109,386
Rheumatology $109,386
Thomas Grader-Beck, M.d, M.D
Rheumatology — Payments: $100,607
Rheumatology $100,607
Lisa Christopher, M.d, M.D
Rheumatology — Payments: $95,869
Rheumatology $95,869
Laura Cappelli, M.d, M.D
Rheumatology — Payments: $37,295
Rheumatology $37,295